Highlights InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Market Closed - Nasdaq Stockholm Other stock markets 11:19:08 2024-05-15 EDT			5-day change	1st Jan Change
0.414 ^SEK	+1.22%		+2.48%	+61.72%

05-07	InDex Pharmaceuticals Holding AB Approves the Election of Karl Tobieson as Board Member	CI
04-26	InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod	02-26	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program	11-21	CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate	23-10-20	MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea	23-10-20	CI
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude	23-10-11	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
InDex Pharmaceuticals Holding AB Announces Positive Results from the Pharmacokinetic (PK) Study	23-08-22	CI
InDex Pharmaceuticals Holding AB Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office	23-08-02	CI
InDex Pharmaceuticals Obtains New European Patent for Inflammatory Bowel Disease Drug	23-08-02	MT
InDex Pharmaceuticals Holding AB Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan	23-05-31	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Index Pharmaceuticals Holding AB Announces Positive Results from a Pharmacokinetic (PK) Study with Cobitolimod	23-03-15	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
InDex Pharmaceuticals Holding AB Updates the Timeline of the Phase III Study CONCLUDE with cobitolimod	23-01-27	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Highlights

Filters